El-Gamal, Mohammed I. Oh, Chang-Hyun 2024-01-19T22:03:02Z 2024-01-19T22:03:02Z 2021-09-03 2018-08-02 1475-6366 https://pubs.kist.re.kr/handle/201004/121049 A series of eighteen pyrrolo[3,2-c]pyridine derivatives were tested for inhibitory effect against FMS kinase. Compounds 1e and 1r were the most potent among all the other tested analogues (IC50=60nM and 30nM, respectively). They were 1.6 and 3.2 times, respectively, more potent than our lead compound, KIST101029 (IC50=96nM). Compound 1r was tested over a panel of 40 kinases including FMS, and exerted selectivity against FMS kinase. It was further tested against bone marrow-derived macrophages (BMDM) and its IC50 was 84nM (2.32-fold more potent than KIST101029 (IC50=195nM)). Compound 1r was also tested for antiproliferative activity against a panel of six ovarian, two prostate, and five breast cancer cell lines, and its IC50 values ranged from 0.15-1.78 mu M. It possesses also the merit of selectivity towards cancer cells than normal fibroblasts. English TAYLOR & FRANCIS LTD ANTIPROLIFERATIVE ACTIVITY CSF-1R INHIBITOR DESIGN JNJ-40346527 RECEPTOR DISEASE CELLS Pyrrolo[3,2-c]pyridine derivatives with potential inhibitory effect against FMS kinase: in vitro biological studies Article 10.1080/14756366.2018.1491563 1 JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, v.33, no.1, pp.1160 - 1166 JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY 33 1 1160 1166 scie scopus 000440741000001 2-s2.0-85051077197 Biochemistry & Molecular Biology Chemistry, Medicinal Biochemistry & Molecular Biology Pharmacology & Pharmacy Article ANTIPROLIFERATIVE ACTIVITY CSF-1R INHIBITOR DESIGN JNJ-40346527 RECEPTOR DISEASE CELLS CSF-1R FMS kinase inhibition pyrrolo[3,2-c]pyridine